Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole in Resectable Esophageal Cancer
NCT05563766Phase 2Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Oct 2024
- Primary completion
- Apr 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of itraconazole in esophageal cancer and gastroesophageal junction cancer, sponsored by VA Office of Research & Development. Primary endpoint: Pathological Complete Response Rate at 20 weeks. Started Oct 2024; status: recruiting.
02
Drugs
itraconazole
03
Conditions
esophageal cancergastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05563766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05563766.